Abiomed Announces First Impella RP Patient Enrolled in Recover Right Study

Abiomed Announces First Impella RP Patient Enrolled in Recover Right Study

DANVERS, Mass., April 1, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD),
a leading provider of breakthrough heart support technologies, today announced
the enrollment of the first patient in RECOVER RIGHT, an Investigational
Device Exemption (IDE) study of Impella® RP (Right Peripheral).

The Impella RP is a percutaneous heart pump that is implanted through a single
access site in the patient's leg and deployed through the venous system,
across the right side of the heart without requiring a surgical procedure.

The RECOVER RIGHT clinical study, which received FDA IDE approval to begin in
November 2012, will enroll 30 patients that present with signs of right side
heart failure, require hemodynamic support, and are being treated in the
catheterization lab or cardiac surgery suite.

The following two patient cohorts will be examined in the RECOVER RIGHT
study:

  1) Patients that develop right side heart failure within 48 hours post-left
  ventricular assist device (LVAD) implantation;

  2) Patients that develop right side heart failure subsequent to
  post-cardiotomy shock within 48 hours post surgery or post myocardial
  infarction.

The first enrollment in the RECOVER RIGHT study was a patient who developed
right ventricular dysfunction after receiving an implantable LVAD.The Impella
RP was implanted at Einstein Medical Center Philadelphia under the leadership
of Mark Anderson, M.D., FACS, Chair of the Division of Cardiothoracic Surgery
at Einstein. The Impella RP implant was performed by Christian Witzke, M.D.,
Director of the Structural Heart Disease Program and Parul Patel, MD.,
Director of the Cardiac Catheterization Laboratory at Einstein Medical Center
Philadelphia.

"This is another example of how Einstein Healthcare Network is committed to
providing the best possible outcomes for patients by conducting clinical
trials to assess the safety and probable benefit of innovative technologies
such as the Impella RP pump," added Dr. Anderson, who is co-principal
investigator of the RECOVER RIGHT study with William O'Neill, M.D., medical
director of the Center for Structural Heart Disease at Henry Ford Hospital.

"The Impella RP gave this patient a level of hemodynamic support that allowed
our heart failure team to treat the patient's right-sided heart failure
quickly in a minimally invasively manner," said Dr. Witzke.

The Impella RP is currently the subject of an investigational device exemption
(IDE) clinical study and is not currently approved for sale in the United
States.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of
medical devices that provide circulatory support.Our products are designed to
enable the heart to rest by improving blood flow and/or performing the pumping
of the heart. For additional information please visit: www.abiomed.com

FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements, including statements
regarding development of Abiomed's existing and new products, the Company's
progress toward commercial growth, and future opportunities and expected
regulatory approvals. The Company's actual results may differ materially from
those anticipated in these forward-looking statements based upon a number of
factors, including uncertainties associated with development, testing and
related regulatory approvals, including the potential for future losses,
complex manufacturing, high quality requirements, dependence on limited
sources of supply, competition, technological change, government regulation,
litigation matters, future capital needs and uncertainty of additional
financing, and other risks and challenges detailed in the Company's filings
with the Securities and Exchange Commission, including the most recently filed
Annual Report on Form 10-K and quarterly report on Form 10-Q. Readers are
cautioned not to place undue reliance on any forward-looking statements, which
speak only as of the date of this release. The Company undertakes no
obligation to publicly release the results of any revisions to these
forward-looking statements that may be made to reflect events or circumstances
that occur after the date of this release or to reflect the occurrence of
unanticipated events.

CONTACT: Susie Lisa, CFA
         Senior Director, Investor Relations and Corporate Development
         978-646-1590
         slisa@abiomed.com
        
         Aimee Genzler
         Corporate Communications Manager
         978-646-1553
         agenzler@abiomed.com

Abiomed Logo
 
Press spacebar to pause and continue. Press esc to stop.